{
  "ticker": "ATX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959902",
  "id": "02959902",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250619",
  "time": "0832",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250619/pdf/06kwrlpwdpmwt3.pdf",
  "summary": "- **Second confirmed complete response (CR)** achieved in Amplia's ACCENT trial for pancreatic cancer.  \n- **CR is extremely rare** in advanced pancreatic cancer.  \n- **Trial evaluates narmafotinib (FAK inhibitor)** + chemotherapy (gemcitabine/Abraxane).  \n- **55 patients enrolled**; Phase 2a ongoing (ORR, PFS, OS as endpoints).  \n- **Previous CR reported earlier in the week** (total of two CRs now).  \n\n*Note: No immediate capital markets impact (e.g., raising, timelines). Material for long-term valuation due to rare efficacy signal.*",
  "usage": {
    "prompt_tokens": 1269,
    "completion_tokens": 133,
    "total_tokens": 1402,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-18T22:52:36.071719"
}